1. Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans.
- Author
-
Tamboli RA, Antoun J, Sidani RM, Clements A, Harmata EE, Marks-Shulman P, Gaylinn BD, Williams B, Clements RH, Albaugh VL, and Abumrad NN
- Subjects
- Acylation, Anti-Obesity Agents administration & dosage, Anti-Obesity Agents adverse effects, Anti-Obesity Agents chemistry, Cohort Studies, Combined Modality Therapy adverse effects, Cross-Over Studies, Energy Metabolism drug effects, Ghrelin administration & dosage, Ghrelin adverse effects, Ghrelin chemistry, Gluconeogenesis drug effects, Glucose Clamp Technique, Human Growth Hormone blood, Human Growth Hormone metabolism, Humans, Infusions, Intravenous, Liver drug effects, Liver metabolism, Muscle, Skeletal drug effects, Muscle, Skeletal metabolism, Obesity, Morbid blood, Obesity, Morbid metabolism, Pancreatic Polypeptide agonists, Pancreatic Polypeptide blood, Pancreatic Polypeptide metabolism, Pancreatic Polypeptide-Secreting Cells drug effects, Pancreatic Polypeptide-Secreting Cells metabolism, Pituitary Gland, Anterior drug effects, Pituitary Gland, Anterior metabolism, Postoperative Care, Preoperative Care, Protein Precursors agonists, Protein Precursors blood, Protein Precursors metabolism, Single-Blind Method, Anti-Obesity Agents therapeutic use, Gastric Bypass, Ghrelin therapeutic use, Human Growth Hormone agonists, Insulin Resistance, Obesity, Morbid drug therapy, Obesity, Morbid surgery
- Abstract
Aims: Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism. Circulating ghrelin concentrations are modulated in response to nutritional status, but responses to ghrelin in altered metabolic states are poorly understood. We investigated the metabolic effects of ghrelin in obesity and early after Roux-en-Y gastric bypass (RYGB)., Materials and Methods: We assessed central and peripheral metabolic responses to acyl ghrelin infusion (1 pmol kg
-1 min-1 ) in healthy, lean subjects (n = 9) and non-diabetic, obese subjects (n = 9) before and 2 weeks after RYGB. Central responses were assessed by GH and pancreatic polypeptide (surrogate for vagal activity) secretion. Peripheral responses were assessed by hepatic and skeletal muscle insulin sensitivity during a hyperinsulinaemic-euglycaemic clamp., Results: Ghrelin-stimulated GH secretion was attenuated in obese subjects, but was restored by RYGB to a response similar to that of lean subjects. The heightened pancreatic polypeptide response to ghrelin infusion in the obese was attenuated after RYGB. Hepatic glucose production and hepatic insulin sensitivity were not altered by ghrelin infusion in RYGB subjects. Skeletal muscle insulin sensitivity was impaired to a similar degree in lean, obese and post-RYGB individuals in response to ghrelin infusion., Conclusions: These data suggest that obesity is characterized by abnormal central, but not peripheral, responsiveness to ghrelin that can be restored early after RYGB before significant weight loss. Further work is necessary to fully elucidate the role of ghrelin in the metabolic changes that occur in obesity and following RYGB., (© 2017 John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF